Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to a Trial of Antidepressant

Status unconfirmed · Phase 3

Conditions studied: Major Depression

In brief

The purpose of this study is to assess the safety and efficacy of risperidone augmentation in patients who have failed to respond or only partially responded to an adequate trial of an antidepressant.

Key facts

Study ID

NCT00174577

Run by

Rhode Island Hospital

People needed

84

Starts

2003-02-01

Expected to finish

2005-02-01

Last updated by the study team

2005-09-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients with major depression or partially remitted depression
• currently receiving an adequate trial of an antidepressant

You may not qualify if…

• diagnosis of bipolar I or bipolar II disorder
• psychotic features
• substance dependence or abuse in the past three months

Where it is running

• Emory University School of Medicine — Atlanta, Georgia, United States
• Mood Disorders Program - Rhode Island Hospital — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.